In previous studies we demonstrated telomerase activity in frozen tissue from head and neck squamous cell carcinoma (HNSCC) and their tumor-free tumor margins. In the present study frozen sections from the same tissues were examined for in situ presence of hTERT. In preliminary investigations we established that the most suitable method of tissue preparation was fixation in acetone and methanol followed by steaming and visualization by APAAP. Most of the assays involved eleven anti-hTERT antibodies and were supplemented with the inclusion of antibodies Ki-67, antinucleolin and CD45. hTERT expression was investigated in the tissues of 61 patients with HNSCC and 37 patients without tumor. Semi-quantitative immunoreactive scores were correlated with telomerase activity. We examined the prognostic significance of hTERT expression with Kaplan-Meier curves and tested the immunological specificity of the antibodies by immunoabsorption with two hTERT peptides and a nucleolin peptide. Nuclear staining of satisfactory distribution and intensity was achieved in seven anti-hTERT antibodies both in the carcinomas and in the squamous epithelia of the tumor resection margins and in the control tissues. Proof of hTERT did not differ from telomerase activity. The telomerase activity demonstrated in tumor-free resection margins and in control tissues did, however, correlate with lymphocytic-monocytic infiltration (CD45 expression). This telomerase activity might be related to nuclear hTERT expression in the squamous epithelium, given that the hTERT score values in the connective tissue tended to be negative. The prognostic significance of hTERT expression demonstrated on paraffin sections from different tumor localizations was not confirmed for the frozen sections of patients with HNSCC. The hTERT specificity of the monoclonal NCL-L-hTERT, whose use as an antibody against hTERT has been questioned, was reexamined with immunohistochemical methods, but the intensity of its immunoabsorption with the nucleolin peptide did not exceed that observed in the other anti-hTERT antibodies.
Introduction
Squamous cell carcinomas in the head and neck region (HNSCC) are characterized by a high rate of loco-regional recurrence and secondary tumors. An important cause of this is field cancerization (1, 2) in the area around the tumor. In order to identify patients at risk, extensive studies have examined the specific biology of the invading tumor front and marginal tissue, and trials are in progress to identify the molecular or immunohistochemical markers best suited for characterizing tumor-free margin tissue (3) (4) (5) (6) (7) (8) (9) .
Telomerase activity was demonstrated in the tumor and in the tumor margin of head and neck squamous cell carcinomas (10) (11) (12) . In earlier studies we looked for a difference in telomerase activity between tumor margin tissue of head and neck tumors, the tumor itself and control tissue (13) (14) (15) . We demonstrated telomerase activity in 30% of 20 tumor-free marginal tissue specimens and in 20 tumor distant tissue INTERNATIONAL JOURNAL OF ONCOLOGY 34: 1257 -1279 Immunohistochemical determination of the appropriate anti-hTERT antibodies for in situ detection of telomerase activity in frozen sections of head and neck squamous cell carcinomas and tumor margin tissues specimens. Proof of telomerase using PCR yields no information about telomerase expression in individual cells, but immunohistochemistry is well suited for the in situ presentation of telomerase positive cells, providing that suitable antibodies are available. This prompted us in the present study to subject the same frozen tissues in which we had demonstrated telomerase activity by PCR-ELISA [TRAP-protocol, Kim et al (16) ] to an immunohistochemical investigation to find out specifically which cells express the catalytic protein subunit of telomerase, human telomerase reverse transcriptase (hTERT). When we started, the only immunohistochemical hTERT results which had been published related to paraffin sections or cells embedded in paraffin (17) (18) (19) (20) (21) (22) . The first challenge was therefore to determine which commercially available antibodies and which method would yield the best nuclear presentation of hTERT in frozen sections. At the same time we wanted to investigate whether proof of hTERT in resection margins was of prognostic relevance.
After we had completed the experimental phase of our study, Wu et al (23) reported that the monoclonal antibody NCL-L-hTERT, which we had considered particularly well suited to our purposes, reacted primarily to nucleolin. This prompted us to carry out additional experiments before interpreting our results and to include the antibodies studied by Wu et al (23) in our study.
Patients and methods
Patients and tumor tissue samples. All tissues examined were taken from the head and neck area with previous consent of the patients in our clinic in the context of diagnostics and therapy. Ninety-six squamous cell carcinoma specimens (40 tumor center tissue specimens with carcinoma and possibly squamous epithelia, 38 tumor-free margin tissues with squamous epithelia and 18 tumor-free tumor-distant tissues with squamous epithelia) were collected from 61 patients in the period from 1994 to 1997 (Table I) . Table I . Characterization of the 61 patients with a head and neck squamous cell carcinoma (HNSCC).
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Sex: M, male; F, female; a Age at tissue harvesting in years; S, staging; G, grading; x, unknown, see TNM classification (24) .
-------------------------------------------------
The entire frozen section series was examined by a tumor pathologist with conventional hemalaun-eosin staining to ensure that carcinoma was present in all tumor center tissue specimens and that the tumor margins and tumor distant tissues were all tumor-free.
We examined tissue of different locations from 61 patients with HNSCC: 51 males (84%) aged 58±11 years and 10 female patients (16%) aged 68±11 years. Forty-eight patients had oral and 13 had extraoral squamous cell carcinomas. Patient age refers to age at the time point of tissue removal. TNM classification (24) and degree of differentiation were established by the Institute of Pathology in our hospital. In the tumor center we evaluated the carcinoma and any squamous epithelium present. In the tumor-free margin and tumor distant tissues we evaluated the squamous epithelium.
Patients and control tissue specimens. For a more critical evaluation of hTERT expression in carcinoma tissues we examined oral and extraoral control tissue from different locations in 37 patients without tumor from our clinic in the period from 1994 to 2004: 20 males aged 36±19 years and 17 females aged 40±20 years. In the control tissue sections we evaluated hTERT in squamous epithelium. We examined 23 oral (2x palate, 5x gingiva, 9x oral mucosa, 2x oropharynx, 2x cheek and 3x margins of tongue) and 14 extraoral tissues (1x eye, 2x skin, 1x lips, 3x nose, 4x ear, 2x scalp and 1x forehead). The tissues were taken with the patients' consent in the context of therapy.
Antibodies and experiments carried out to optimize frozen section preparation of squamous cell carcinomas (Table II) . We used the frozen sections from squamous cell carcinomas in which we had previously demonstrated telomerase activity in PCR-ELISA (13) (14) (15) . For optimal immunohistochemical results we used the four commercially available anti-hTERT antibodies, the three polyclonal rabbit antibodies [Ab 1, Ab 2 and Ab 4 (Table II) ] and one monoclonal murine antibody [Ab 3 (Table II) ]. These were the antibodies used by Hiyama et al (17) , , Yan et al (21) and Park et al (22) for paraffin sections and cell cultures embedded in paraffin to determine hTERT with the EnVision demonstration system (DakoCytomation, Denmark). Using the same preparatory processing and EnVision we achieved only cytoplasmic staining in the squamous cell carcinomas and only in those epithelial and carcinoma cells with a more or less stained background. We therefore reverted to APAAP (25) (26) (27) (28) , which had proved successful in earlier immunohistochemical examinations. The purpose was to achieve nuclear and/or nucleolar presentation of hTERT with commercial antibodies. Fixation for 9 min in methanol and subsequently 1 min of aceton fixation at -20˚C proved the most successful method, more suitable than acetone alone, methanol alone or 4% paraformaldehyde at 4˚C or -20˚C. Nonetheless, additional pretreatment of the frozen sections was necessary. The best nuclear presentation was achieved when the frozen sections were pretreated for 30 min in a steamer (Braun Multi Gourmet Plus FS20, Kronberg, Germany) in TRS-Puffer S1699 (Dako Cytomation) pH 6.1. Results of pretreatment in the autoclave or microwave in various buffers with and without Tween and with and without EDTA were less successful. This procedure was maintained throughout the study and with all newly acquired anti-hTERT antibodies which became commercially available (Ab 5 to Ab 11) (Table II) .
The results of immunohistochemistry were compared with control antibodies: a monoclonal mouse anti-human Ab 12 against Ki-67, a polyclonal rabbit antibody Ab 13 against nucleolin and a monoclonal mouse Ab 14 against leukocyte common antigen (Table II) . Ki-67 was used to prove proliferation and for better recognition of carcinomas in the tiny frozen sections; CD45 for better visualization of lymphocyte mononuclear infiltration. After the monoclonal anti-hTERT antibody (clone 44F12, code NCL-hTERT, Ab 3) was described in the study by Wu et al (23) as an antibody against nucleolin, we expanded our investigation and incorporated an anti-nucleolin antibody (Ab 13) to clarify this issue.
Immunohistochemistry and immunoreactive score values (IRS).
All incubation steps taken in the immunohistochemical staining process were performed in a humidified chamber. To block non-specific reactions we incubated sections at room temperature for 20 min with the ready-made X0909 blocking buffer (DakoCytomation). Between each step the sections were rinsed thoroughly three times in TBS buffer, pH 7.6 (Trisbuffered saline, concentrated 10X, S3001 DakoCytomation; with pH of dilution at 7.6). All antibodies were diluted in S2022 (DakoCytomation, ready to use). We determined the optimal dilution for each antibody in accordance with the product data sheets. Antibodies were incubated for 60 min at 37˚C in the drying oven and then for 30 min at room temperature. In the case of some antibodies only a limited number of tissues were stained.
The alkaline phosphatase anti-alkaline phosphatase [APAAP (25) ] used to detect the antigen antibody reaction was carried out as follows: the two bridge antibodies were incubated at room temperature at 1:40 (diluted in antibody dilution plus 5% AB serum by Biotest AG, Dreieich, Cat. 805135/Germany). For sections with polyclonal primary antibodies (for Ab 1, Ab 2, Ab 4 to Ab 9, Ab 13) monoclonal mouse anti-rabbit bridge antibodies (DakoCytomation M0737) were applied and for sections with monoclonal antibodies (for Ab 3, Ab 10, Ab 11, Ab 12, Ab 14) polyclonal rabbit anti-mouse bridge antibodies (DakoCytomation Z0259) were used. Sections were then incubated for 40 min with the monoclonal APAAP complex (DakoCytomation D0651), diluted 1:100 in antibody dilution plus 5% inactivated fetal calf serum (FKS, Biochrom AG, Berlin, S0115, Germany). Substrate development lasted approximately 20 min (gauged by visual judgment) with DakoCytomation K0624 substrate plus 2 additional drops of levamisol (K5000 by DakoCytomation) per 3 ml of substrate. The sections were counterstained with hemalaun (DakoCytomation S2020) for 5 min with subsequent blueing for 5 min in tap water.
All score values given for anti-hTERT, Ki-67 and antinucleolin refer exclusively to nuclear and/or nucleolar stainings in the carcinomas or epithelia and the expression of CD45 in complete tissues. Based on our previous immunohistochemical studies with other antibodies (26) (27) (28) we used the immunohistochemical evaluation by Remmele et al (29, 30) . The evaluation of the sections was performed three times at different time points by an independent examiner and was Table II. Overview of primary antibodies used.  -----------------------------------------------------------------------------------------------------Ab  Antibodies  Source, code  Characterization  Working  code  dilution  ---------------------------------------------------------------------------------------------------- Immunoabsorption to test anti-hTERT antibody specificity. Few commercial peptides were available for these tests: a hTERT peptide EST21-P (Alpha Diagnostics), 16-aa peptide of human EST2. This peptide was used as a homologous immunogen for EST21-A, our Ab 2; a hTERT peptide ab24029 (Abcam, USA), a synthetic peptide derived from within residues 550-650 of human telomerase, and was used as a homologous immunogen for ab23699, our Ab 8; and a nucleolin peptide ab25315 (Abcam), a synthetic peptide derived from within residues 1-100 of human nucleolin, and was used as a homologous immunogen for ab22758 nucleolinAb, our Ab 13. Using Ki-67 antibodies by DakoCytomation (Ab 12) we tested the suitability of albumin as a control for absorption. We used a 30% albumin solution (Sigma A-334424, USA) diluted 1:30 in isotonic buffered saline. The immunoreactive score value of Ki-67 expression was the same after absorption in the albumin solution as it was before.
We conducted immunoabsorption following the protocols of Alpha Diagnostics (31) and Abcam (32) with some modification, and the details provided by Frost et al (33) . The antibody-peptide mixtures were incubated for 2 h at 37˚C and overnight at 4˚C to facilitate absorption of antibodies binding at higher and/or lower temperatures. For control purposes we substituted peptide with the same quantity of albumin (Sigma A-3424) and used the same volume of antibody dilution (S2022, DakoCytomation). Following incubation we centrifuged the mixtures for 15 min at 15000 rpm at 4˚C and applied immunohistochemical techniques on the absorbed portions (including the control portions with albumin) at the usual dilution. Squamous cell carcinomas (30 tissues) and control tissues (13 tissues) with squamous epithelium were examined with the absorbed antibodies. We evaluated the immunoabsorption on the basis of immunoreactive scores of tissues before and after absorption. IRS unchanged after absorption: immunoabsorption of antibody, negative; IRS after slight absorption, 1+; IRS after absorption reduced by half and more, 2+ to 3+. Only results of 2+ and 3+ were considered adequate for our purpose.
Determining telomerase activity in the same frozen tissue samples. As described above (13, 14) 
aa, amino acid; Ab, antibody; KLH, keyhole limpet hemocyanin. (Table II) by IRS in tumor center tissues of oral and extraoral squamous cell carcinomas (patients data see Table I ). 
a TA-TC, telomerase activity in total tumor center; 0, negative, TA 0-150 mOD; 1+, TA 150-450 mOD; 2+, TA 450-750 mOD; 3+, TA 750-1050 mOD; 4+, TA above 1050 mOD; TC, tumor center; IRS, immunoreactive score; Ab, antibody: Table II ; -, not examined.
groups for the statistical comparison of incidence (immunoreactive score values and telomerase activity) in the ¯2 test or Fisher exact tests. We divided all values into two groups: for group 0, values < median value and for group 1, values ≥ median value. We chose the median value as the cut-off value because the score values were not normally distributed.
For testing the prognostic statement made by these values in the Kaplan-Meier curves we used the patient outcome documentation in our hospital. We recorded the number of months between tissue excision and relapse. Several patients, particularly patients with extraoral HNSCC, withdrew from the follow-up. We applied to the Kaplan-Meier curves with the hTERT-group 0 (values < median value) and hTERT-group 1 (values ≥ median value).
Test results with p≤0.05 were rated as statistically significant.
Results
Since proof of hTERT expression was very weak with both the first antibody (polyclonal anti-telomerase Ab, Oncogene code PC 563) and the fifth antibody (polyclonal anti-TERT Ab H-231, Santa Cruz code sc-7212) (Table II) , we used these two antibodies only for a few sections and did not detail the results.
The score values for all tissues without carcinoma cells and without squamous epithelium were very low (tendency towards 0) and for this reason were neither listed nor presented in a graph. Tables III and IV summarize the immunoreactive score values for hTERT expression in comparison to telomerase activity as determined by PCR in Table IV . Telomerase activity in mOD in tumor center tissues, expression of hTERT and Ki-67 by IRS of squamous epithelia (SE) in the oral and extraoral squamous cell carcinoma tissue samples (see Table I ).
Results for tissues from tumor patients: hTERT expression in the tumor center.
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a TA-TC, telomerase activity in total tumor center tissue; 0, negative, TA 0-150 mOD; 1+, TA 150-450 mOD; 2+, TA 450-750 mOD; 3+, TA 750-1050 mOD; 4+, TA above 1050 mOD; IRS, immunoreactive score; Ab, antibody: Table II ; -, no squamous epithelium in section or not examined.
the same tumor center tissue samples. Patient data are given in Table I .
Telomerase activity and hTERT expression yielded with antibodies Ab 3, Ab 6, Ab 8 and Ab 11 as well as with antinucleolin antibody (Ab 13) were higher in oral carcinoma (n=33, patients nos. 1-33) than in extraoral carcinoma (n=7, patients nos. [34] [35] [36] [37] [38] [39] [40] . With the other hTERT antibodies (Ab 2, Ab 4, Ab 7, Ab 9, Ab 10) the values were either the same or higher in extraoral tissue. The U test (or t-test) rendered no significant difference in IRS between oral and extraoral carcinoma tissue: either in anti-hTERT scores, scores for telomerase activity, scores for Ki-67, anti-nucleolin or CD45. The p-values ranged between 0.136 and 1.000. Localization of the tissue was therefore disregarded in the subsequent results.
The score values of individual antibodies were very heterogeneous, both in squamous cell carcinoma tissue and the squamous epithelium of the same tissue sample, and antibodies for the most part were not distributed normally (Tables III and IV) . For this reason the median values for hTERT-expression in Fig. 1 were depicted as graphics.
IRS median values in Fig. 1 reveal that the polyclonal antibodies anti-EST2 (Ab 2) and the anti-telomerase Ab by Calbiochem (code 582000, Ab 6) are least suited for hTERT demonstration in frozen sections and show significantly less hTERT expression in the tissues than do other antibodies. hTERT expression with both these antibodies was however higher than that observed with the two other antibodies not included in Tables III and IV, namely The score values for hTERT expression with all antihTERT antibodies were higher in carcinoma than in normal or partly dysplastic squamous epithelium present in the same tissue sample (Tables III and IV, Fig. 1 ). In the U test (or t-test) hTERT expression in carcinoma was, however, not always significantly higher than in squamous cell tissue of the same piece of tissue: Ab 2, p=0.412; Ab 3, p=0.056; Ab 4, p=0.081; Ab 6, 0.463; Ab 7, p=0.032; Ab 8, p=0.528; Ab 9, p=0.024; Ab 10, p=0.012 and Ab 11, p=0.043.
In the ¯2 test we explored whether there is a statistical correlation between hTERT expression in the individual antibodies and telomerase activity in squamous cell carcinoma, and formed two groups for this purpose (see statistical evaluation): p-values between 0.086 and 0.876. It appeared to be the lowest (p=0.086) with the monoclonal antibody (clone 2C4) NB 100-317 (Ab 11). This might be because this particular antibody lot had to be filtered and centrifuged to remove foreign particles.
In the same manner we examined expression of Ki-67, nucleolin and CD45 (Table III) . No statistical difference was found in the tumor center between the scores with Ki-67 (Ab 12) and with anti-nucleolin (Ab 13): U test, p=0.828. However, both these scores differed significantly from the proof of lymphocytic infiltration as indicated by the scores Table II. with CD45 (Ab 14) of all tissue types of the tumor centers: U test, p=0.008 and 0.041. In the ¯2 test (or Fisher exact test) the hTERT expression was compared with the expression of the control antibodies. In the comparison of both Ki-67 and of nucleolin scores with hTERT score values a correlation appears ranging in significance from slight to high. A significant divergence (p=0.036) appears between nucleolin expression and hTERT scores with the monoclonal anti-hTERT antibody NCL-hTERT (Ab 3). This contradicts observations made by Wu et al (23) . The other p-values are located between 1.000 and 0.191. Between the nucleolin and CD45 expression and telomerase activity there is also a statistical correlation, but not between Ki-67 and telomerase activity (p=0.05).
Expression of hTERT in tumor-free tumor margin and tumor distant tissue from the patients with squamous cell carcinoma.
Table V summarizes the immunoreactive scores for hTERT expression in the squamous epithelium of the carcinoma-free tumor margin and carcinoma-free tumor distant tissue. The scores for Ki-67 in squamous epithelium and evidence of lymphocytic infiltration by CD45 in the tissue samples are also shown. Fig. 2 presents the median values for hTERT expression on squamous epithelium in these tissues.
Evidence for hTERT expression in squamous epithelium is also more moderate as detected by both polyclonal anti-hTERT antibodies, the anti-EST2 (Ab 2) and the anti-telomerase Ab from Calbiochem (code 582000, Ab 6): Fig. 2 (see Fig. 1 ). A comparison of hTERT score values, as determined with the U test (or t-test) renders no significant difference between hTERT score values for squamous epithelium in the tumor center, in the tumor margin or in tumor distant tissue, i.e., the values for hTERT expression in these regions are correlated: the hTERT expression in the squamous epithelium adjacent to the carcinoma is statistically no higher than that in the more distant tissue: p-values between 0.114 and 0.972.
Using the U test (or t-test) we also compared score values for expression of Ki-67 in squamous epithelium and proof of CD45-positive lymphocytic cells in the same tissue areas. Evidence of proliferating epithelial cells (Ki-67 scores) did not differ significantly among the three regions, but lymphocyticmonocytic infiltration was the lowest in the tumor distant region: p=0.974 (Ki-67) and p=0.068 (CD45). There is a correlation between the level of hTERT scores and the intensity of CD45 staining of the lymphocytic infiltration in tumor margin and tumor distant tissue. The correlation was significant only between CD45 and the lowest hTERT scores observed with the antibodies Ab 2 and Ab 6 (p<0.001).
With the ¯2 test we addressed the question of whether there is a correlation between hTERT expression, Ki-67 score values in epithelium, evidence of CD45 in the resection margin and tumor distant tissue, and telomerase activity in the same tissue. No statistical relation was found between telomerase activity in tumor margin tissue and hTERT expression when the polyclonal anti-hTERT antibody EST-2 (Ab 2) was used (tumor margin p=0.038, tumor distant values p=0.103), and only a slight correlation was found with the monoclonal antibody code NCL-hTERT (Ab 3): p=0.055 (tumor margin) and p=0.103 (tumor distant tissues). We did find a statistical relationship between hTERT expression with the other hTERTantibodies and telomerase activity in the same tissue (p-values of tumor margin between 0.884 and 0.421 and tumor distant tissues between 1.000 and 0.580). The Ki-67 score values (tumor margin p=0.052 and tumor distant tissues p=0.580) and the CD45 score values for lymphocytic infiltration (tumor margin p=0.751 and tumor distant tissues p=1.000) were also connected to telomerase activity in the same tissue. This correlation was the weakest in squamous epithelium of the tumor margin. Table II . Table V . Telomerase activity in mOD, expression of hTERT and of Ki-67 in squamous epithelium from the tumor-free margins (TM) and tumor-free tumor distant tissues (TD) of squamous cell carcinomas as well as of lymphatic infiltration (expression of CD45 in complete sections), see Table I . . TA  a -IRS  IRS IRS IRS  IRS  IRS  IRS TA  a -IRS  IRS IRS  IRS IRS  IRS  IRS  TM Ab 2 -------29  0  9  12  9  2  1  1  6  1+  0  1  9  2  1  8  12  31  3+  2  5  7  3  6  12  8  0  2  12  7  3  6  8  4  32  0  5  12  3  7  5  12  16  --------36  1+  0  5  6  3  5  4  12  --------38  0  ------2  0  2  3  ---12  3  39  1+  0  6  2  2  3  8  8  0  3  12  2  2  3  2  8  40  2+  3  8  5  2  0  8  1  --------41  0  -9  ---0  0  --------42  1+  2  8  5  2  5  4  12  --------43  0  2  1  1  1  1  12  1  --------44  2+  5  5  11  5  6  8  8  --------45  1+  1  8  8  2  16  16  12  --------46  0  ----11  4  8  --------47  1+  8  11  8  8  10  12  12  --------48  3+  6  7  1  1  5  8  12  0  1  9  1  1  5  12  12  49  2+  --6  --12  0  --------50  3+  11  4  4  4  5  12  8  --------51  1+  4  10  3  -3  8  12  --------52  0  1  2  0  --8  3  --------53  0  1  14  5  4  14  12  10  --------54  2+  5  7  10  10  10  8  4  --------55  2+  0  1  0  0  0  8  16  0  -10  0  0  0  12  4  56  1+  12  14  14  5  11  16  14  --------57  3+  4  6  6  2  6  8  8  1+  0  0  6  2  6  4  0  58  2+  2  0  8  6  -2  4  --------59  1+  6  12  12  6  6  8  4  --------60  1+  0  8  8  4  8  8  12  --------61  4+  2  14  2  0  14  12 Table VI and median values are illustrated in Fig. 3 . Fig. 3 illustrates the low sensitivity of antibodies Ab 2 and Ab 6, disqualifying them for detection of hTERT expression in control tissues. As already distinguishable in Fig. 3 (see Figs. 1 and 2 ) the score values for the antibodies Ab 2 and Ab 6 are consistently lower than those for the other antibodies.
The immunoreactive scores of control tissue samples also were very heterogeneously distributed in the squamous epithelium itself and varied with the individual antibody. Control  TA   a   IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  no. Ab 2 Ab 3 Ab 4 Ab 6 Ab 7 Ab 8 Ab 9 Ab 10 Ab 11 Ab 12 Ab 13 Ab 14 
a TA, telomerase activity; 0, negative, TA 0-150 mOD; 1+, TA 150-450 mOD; 2+, TA 450-750 mOD; 3+, TA 750-1050 mOD; 4+, TA above 1050 mOD; Ab, antibody: Table II ; IRS, immunoreactive scores; -, not examined or no squamous epithelium in section.
When the immunoreactive score values of oral and extraoral control tissues were compared in the U test (or the t-test), it was frequently the squamous epithelium of oral tissue which in most tests showed the highest expression. This difference, however, was rarely significant (oral scores were higher with Ab 6, p=0.052; and significantly higher with Ab 7, p=0.010; extraoral scores were significantly higher with Ab 11, p=0.043). With all other antibodies, the difference in expression between oral and extraoral squamous cell carcinoma was insignificant (p-values between 0.103 and 0.886).
Telomerase activity and the expression of Ki-67 (Ab 12), nucleolin (Ab 13) and CD45 (Ab 14) were higher in oral control tissues than in extraoral tissues (Table V) . This difference was significant for telomerase activity (p=0.023), Ki-67 (p=0.006) and CD45 expression (p=0.032) but was not significant for nucleolin expression (p=0.434).
The ¯2 test between telomerase activity in the control tissues and the hTERT-score values as well as between telomerase activity in the control tissues and the scores for control antibodies showed a connection (all p-values were >0.05).
Testing the specificity of anti-hTERT antibodies by immunoabsorption. While this study was in progress, Wu et al (23) reported that the monoclonal anti-hTERT antibody NCLhTERT clone 44F12 (Ab 3) primarily identifies nucleolin rather than hTERT. The Wu group supported this with massspectrometry evidence as well as gel analysis and immunofluorescence. Since immunohistochemical in situ presentation requires an antigen-antibody reaction, we expanded our study to include immunoabsorption of some of our antibodies with two commercially available peptides and one nucleolin peptide. We used the hTERT peptide EST21-P, homologous to the anti-hTERT antibody (Ab 2), the hTERT peptide ab24029, homologous to anti-hTERT antibody Ab 8 and the nucleolin peptide ab25315, homologous to the anti-nucleolin antibody (Ab 13). After immunoabsorption with hTERT peptide EST 21-P and nucleolin peptide, the amount of resulting precipitate was negligible. This was the case both with the homologous antibodies and with the other anti-hTERT antibodies. There was, however, significant precipitate, i.e., precipitating antigenantibody complexes, after immunoabsorption with the hTERT peptide and the homologous antibody Ab 8 and also with the anti-hTERT antibodies Ab 4, Ab 7, Ab 9 and Ab 10. Somewhat less precipitate resulted with Ab 11. The immunoabsorption of Ab 3 exhibited significant precipitate. In contrast, no precipitate was deposited after immunoabsorption of the antinucleolin antibody, either with the two hTERT peptides or with the homologous nucleolin peptide.
After immunoabsorption and centrifugation of the precipitate, we determined the immunoreactive score values with the absorbed antibodies and compared them before and after absorption. We then determined the percentage of tissues with score values which were markedly lower after absorption than before (2+ or 3+ inhibition of score values by absorption). After incubation with peptide, some of the antibodies showed no or little change in score value (rated as negative immunoabsorption). This might be because the antibody corresponded only partially to the peptide, or, as is more likely, because too little peptide was applied. This was clearly evident with the polyclonal antibodies EST21-A (Ab 2) and ab23699 (Ab 8), Table II. which even with the homologous peptide used in their production showed only 60% and 59% absorption respectively. Adding inert albumin to the antibodies instead of peptide did not reduce their score values. Since the reduced score values resulting in carcinoma tissue and in the squamous cell tissues from the controls were comparable, we summarized absorption results for the anti-hTERT antibodies together in Fig. 4 . Fig. 4 shows the percentage of score values after immunoabsorption. The figure shows that only the anti-hTERT Ab 11 (code NB 100-317) was completely absorbed by the hTERT peptide EST-21-P and only the anti-nucleolin antibody (Ab 13) was completely absorbed by the homologous nucleolin peptide ab25315. The score values for antibodies Ab 4 and Ab 9 to Ab 11 remained unchanged after absorption with the nucleolin peptide ab25315 antibody.
The nucleolin peptide ab25315 absorbed three of the seven anti-hTERT antibodies examined. The monoclonal antibody NCL-hTERT (clone 44F12, Ab 3), characterized by Wu et al as an anti-nucleolin (23) , absorbed 21% of the number of sections examined with the nucleolin peptide (79% was not absorbed, Fig. 4 ). Similar immunoabsorption (17%) was observed for the polyclonal ab177 (Ab 7, 83% not absorbed) and a stronger absorption (57%) by the polyclonal ab23699 (Ab 8, 43% not absorbed). Conversely, the anti-nucleolin antibody (Ab 13) is only minimally absorbed (8% of the tissue examined, 92% not absorbed) by the hTERT peptide ab24029, the immunogen for the polyclonal ab23699, Ab 8.
Localizing hTERT with selected anti-hTERT antibodies.
The distribution of hTERT-positive cells was usually very heterogeneous in the individual squamous cell carcinomas irrespective of the antibody used. Where squamous epithelium in tissues from tumor patients or in control tissue was still normal, the hTERT-positive cells were limited to one or two basal layers. However, in hyperplastic or more or less severely dysplastic squamous epithelium, suprabasal hTERT was also evident, or was spread over the entire squamous epithelium. Fig. 5 compares the patterns of expression as indicated by the individual anti-hTERT antibodies after pretreatment of the frozen sections in the steamer and visualization in APAAP (25) . Fig. 5 shows some of the immunohistochemical illustrations collected in carcinoma tissues. Application of the polyclonal Ab 2 (not illustrated), polyclonal Ab 4 (Fig. 5b) , polyclonal Ab 8 (Fig. 5d) , polyclonal Ab 9 (Fig. 5e ), monoclonal Ab 10 ( Fig. 5f ) and monoclonal Ab 11 (not illustrated) induced the typical immunohistochemical pictures of carcinoma and (not illustrated) epithelia staining of the entire nucleus including cytoplasmic staining. With the Ab 4 and Ab 11 we were also able to distinguish non-specific staining in the uppermost keratinous squamous epithelia or background (especially with Ab 4). Positive staining was also observed with Ab 4, Ab 8 Ab 9 and Ab 11 in endothelia, lymphocytes/histiocytes or blood cells (not illustrated).
The immunohistological pictures presented by the polyclonal Ab 6 are similar to Ab 4 but clearly weaker, with the background also clearly weaker than with Ab 4. The pictures with the polyclonal Ab 7 (Fig. 5c ) and with the monoclonal Ab 10 (Fig. 5f ) demonstrated nuclear staining of the entire nucleus, with but little background staining or non-specific staining in the uppermost keratinous squamous epithelia (not illustrated). Ab 10 also stained endothelia, lymphocytes/ histiocytes in connective tissues.
The immunohistochemical pictures of monoclonal Ab 3 ( Fig. 5a ) were nuclear, with characteristic marking of nucleoli only. Background staining was not observed.
Prognostic significance of immunohistochemical proof of hTERT protein.
In order to determine the prognostic significance of hTERT expression we applied Kaplan-Meier curves as described under Patients and methods for each antibody in the carcinoma tissue, in the squamous epithelium in tumor center and tumor margin tissue. The Kaplan-Meier analyses rendered no significant correlation between increased hTERT expression and poor prognosis. The period without recurrence was not significantly shortened in patients with higher hTERT expression (scores ≥ the median value). The Kaplan-Meier curves in Fig. 6 show that the increased hTERT expression obtained with the polyclonal Ab 7 (code ab177) correlated with a poor prognosis. The period without recurrence was shortened in patients with hTERT expression ≥ IRSmedian. 
Discussion
The telomeric repeat amplification protocol (TRAP) developed in 1994 by Kim et al (16) made possible the reproducible demonstration of telomerase in larger studies of various tumors. Since then researchers have been working on hTERT evidence with RT-PCR (12, 18, 19, (36) (37) (38) (39) (40) or on proof of telomerase-positive cells by in situ hybridization (12, (36) (37) (38) (39) (40) . This period has also seen the advent of laboratory manufacturing (33, (41) (42) (43) (44) (45) (46) or commercial (17-22) production of anti-hTERT antibodies for use in immunohistochemistry.
The purpose of the present study was the in situ demonstration of telomerase activation in frozen sections from head and neck tumors and comparison with control tissue from tumor-free patients. In previous studies with these same tissues we had proved telomerase activity in PCR-ELISA (13-15) and determined the corresponding semiquantitative extinction values. Non-carcinomatous tumor margin tissue showed telomerase activation. We wanted to identify the cells responsible for this activity in non-carcinomatous tumor margin and tumor distant tissue and chose as our method the immunohistochemical proof of hTERT, the catalytic subunit of telomerase, in the same frozen tissues in which we had already demonstrated telomerase activity. We were obliged to use commercial antibodies. Some anti-hTERT antibodies gradually became available on the market through the course of our study. At that time, non-commercial (33, (41) (42) (43) (44) (45) (46) or commercial (17) (18) (19) (20) (21) (22) antibodies had only been used for hTERT-proof in paraffin slices or in paraffin-embedded cells.
Immunoreactive hTERT score values in tissue from patients with HNSCC. The relatively heterogeneous tissue examined from patients with an HNSCC (patient data in Table I ) was derived from tumors with various staging and grading. The squamous epithelium in these tissue samples also evidenced different histopathological pictures. The small patient number did not allow subdivision of hTERT results into individual groups. We correlated hTERT expression both between the different tissue regions (tumor center, carcinoma-free adjacent tumor margins and tumor distant tissues) and with telomerase activity (Tables III-V) . It is clear from hTERT expression in carcinoma (Table III, Figs. 1 and 5) , in squamous epithelial tissue of the tumor center tissue (Table IV and Fig. 1) , squamous epithelial tissue of the tumor margin (Table V and Fig. 2 ) and squamous epithelial cells of tumor distant tissue (Table V and Fig. 2 ) that the antibodies Ab 4 (code 582005) and Ab 7 (code ab177) can be used for proof of hTERT. Notwithstanding the re-evaluation of anti-hTERT antibodyspecificity by Wu et al (23) , Ab 3 (NCL-L-hTERT) can be used also for hTERT-detection. The antibodies Ab 8 to Ab 11, which we used only for tumor center tissue (carcinoma and squamous epithelium), also showed unambiguous immunohistochemical hTERT scores ( Fig. 1 and Table III) . hTERT scores were higher in the carcinoma than in the squamous epithelial tissue in the same tissue pieces. hTERT expression in the squamous epithelium of tumor margins and tumor distant tissue, however, was higher than or equal to the squamous epithelium in carcinoma tissues.
The patterns of hTERT expression in these frozen sections did not vary essentially from the picture presented on the paraffin sections from HNSCC already examined (47) (48) (49) (50) (51) . With an antibody not described in more detail, Nguyen et al (47) demonstrated hTERT in all carcinomas examined and, albeit significantly less, in dysplastic squamous epithelia. The authors (47) suppose a correlation between hTERT expression and tumor stage. Kumar et al (48) examined hTERT expression at different stages of oral carcinogenesis using the antibody NCL-hTERT (our Ab 3, Table II ) and were able to differentiate between hTERT expression in normal oral mucosa and that in different histological stages of oral carcinogenesis. The authors evaluated only sections in which they had demonstrated more than 50% hTERT-positive nuclei.
Luzar et al (49) also used hTERT proof with the antibody NCL-hTERT for their study on the carcinogenesis of the larynx carcinoma. They proved an increase in hTERT expression from normal epithelium (average index 0.17) up to that in the carcinoma (average index 0.96). In their extensive study, Chen et al (50) also used the NCL-hTERT antibody and differentiated their results by quantifying the proportions of cytoplasmic and nuclear staining. They examined 21 tissues from oral mucosa, 116 tissues of varying grades of dysplasia and 62 oral SCC tissues and determined hTERT scores comparable with those detected in our study. Immunohistochemical scores are known to be higher on paraffin sections than on frozen sections, a phenomenon which we have already confirmed in earlier investigations (27, 28) . For their scores, Chen et al (50) multiplied the percentage of positive cells by staining intensity, while, in accordance with Remmele et al (29, 30) , we reduced the percentage of positive cells between 0 and 100% to 0 to a maximum of 4 and then multiplied this by staining intensity. Our scores lay under the values of Chen et al (50) for the paraffin sections. Using the antibody NCL-hTERT Chen et al determined an average nuclear score of 80±14 in normal oral mucosa, 91±23 in light dysplasia, 91±23 in moderate dysplasia, 93±21 in severe dysplasia and 86±35 in carcinoma tissues.
In our study, the highest hTERT scores with the same NCL-hTERT antibody were found in carcinoma tissue, with an average value of 8.5±3.8, followed by squamous epithelial tissue in the tumor center with 6.8±3.8 ( Fig. 1) , tumor margin tissue with 7.4±4 and tumor distant tissue with 6.8±4 (Fig. 2) . Chen et al (50) also found cytoplasmic scores ranging in ascending order from those found in normal mucosa up to those for carcinoma. We did not make quantitative evaluations of cytoplasmic staining, we observed however that there was no or only little cytoplasmic staining with the NCL-hTERT antibody (Ab 3).
In the study by Freier et al (51) a non-specified polyclonal anti-hTERT antibody by Abcam was used (see our Ab 7 and Ab 8, Table II ). The authors compared immunohistochemical results with those attained by fluorescence in situ hybridization and were able to establish cytoplasmic and nuclear hTERT expression (71%) on 218 squamous cell carcinomas in the oral region which were significantly higher than that on squamous cell carcinomas in larynx samples (35/89; 36%). The authors concluded that higher and more frequent hTERT expression was a suitable target for anti-neoplastic therapy.
Correlation of hTERT score values and telomerase activity in HNSCC.
None of the few immunohistochemical studies dealing with hTERT on squamous cell carcinomas in the head and neck has correlated its results to telomerase activity (47) (48) (49) (50) (51) . Gonzalez-Quevedo et al (52) , who demonstrated hTERT in the RT-PCR in various tumors, pointed to a direct correlation between telomerase activity (determined in TRAP-ELISA) and hTERT. This was congruent with the findings of Fujimoto et al (53) . The authors also demonstrated hTERT in diverse cell cultures, including cell cultures from oral SCC and oral keratinocytes, by RT-PCR and found a good correlation with the telomerase activity determined in TRAP. In carcinoma tissue, the telomerase activity we found by TRAP-ELISA in HNSCC (Tables III and IV) correlated with the hTERT expression we found by immunohistochemistry with all antibodies (¯2 test: p>0.05). The lowest correlation was found with antibody code NB 100-317 (Ab 11: ¯2 test: p=0.086). In surgical tumor margin tissue, the hTERT scores with the antibody EST21-A (Ab 2) and the level of telomerase activity differ significantly: ¯2 test: p=0.038. All further hTERT scores in the tumor margin and tumor distant tissues (Table V) correlate in varying degrees with telomerase activity. We ascertained in our study, as had other authors in regard to diverse tumors (21, 52, (54) (55) (56) (57) , that the absence of telomerase activity [under 150 mOD (13-15)] does not always coincide with the absence of hTERT expression and vice versa. Shay et al (58) did not always observe a correlation between the levels of telomerase and those of hTERT expression, while Etheridge et al (59) found a strong correlation between telomerase activity and hTERT expression. Only rarely did Wu et al (60) demonstrate hTERT with RT-PCR in telomerasenegative tissues taken from various skin tumors.
With the antibody code 582005 (our Ab 4) hTERT scores did not always correlate with the telomerase activity demonstrated, a result again conforming to Yan et al (21) , who moreover also demonstrated hTERT expression in telomerasenegative tissue. This non-correlation was also observed with other antibodies in our study.
Correlation between hTERT score values and clinical outcome of patients with HNSCC. We examined Kaplan-Meier curves for a relationship between our hTERT score values for the individual antibodies and patient outcome. As determined using the antibodies Ab 2, Ab 3, Ab 7, Ab 10 and Ab 11, periods without relapse were shorter, if not significantly shorter, for patients with high hTERT expression in the carcinoma than those for patients with lower hTERT expression. However, we also observed the opposite, i.e., that higher hTERT expression on the squamous epithelium in carcinoma tissue pieces was associated with longer periods of remission (Ab 3). Between the extended Kaplan-Meier curves there were no significant differences. Only the comparison (in the Kaplan-Meier curves) of hTERT expression on carcinoma in the tumor center with the polyclonal anti-hTERT antibody code ab177 (our Ab 7, Table II ) approximated any significance. Survival times were distinctly shorter with higher hTERT expression than with lower hTERT expression (Fig. 6) .
Pannone et al (61) found no connection between the immunohistochemically determined hTERT and patient outcome with oral HNSCC after surgery therapy. The only exception to this was one high hTERT expression noted in tumor staging I which was associated with poor prognosis. Examining oral HNSCC patients, Chen et al (50) correlated significantly shorter survival times and higher nuclear hTERT expression with the antibody NCl-hTERT (clone 44F12, Ab 3, Table II ). Numerous studies on various tumors attest to a connection between hTERT expression (determined in immunohistochemistry or in RT-PCR) and prognosis (18-20, 48,50,54,62-64) . Nor was the controversial NCL-hTERT antibody (48, 50, 63, 64 ) the only antibody used in immunohistochemical examinations. A correlation between patient outcome and higher hTERT IRS scores emerged as well with antibody code sc-71212 (H-231, our Ab 5) (54,62) and antibody code 582005 [our Ab 4 (20, 64) ]. These results are corroborated by very few authors. Toomey et al (65) explored hTERT expression in patients with an operable lung carcinoma using an anti-hTERT antibody by Santa Cruz (code C20) and found no correlation in the Kaplan-Meier curve between high hTERT expression and patient outcome. Tabori et al (66) , using our Ab 3 in ependymomas, were able to demonstrate a significantly shorter survival time in patients with higher hTERT expression (p=0.05). In patients with a mamma carcinoma, hTERT as demonstrated by Elkak et al (67) using the NCL-hTERT antibody (our Ab 3) did not correlate in the ¯2 test with lymph node status, grading or tumor size. Mavrommatis et al (68) observed that nuclear hTERT (anti-hTERT code sc-7215 by Santa Cruz) was a good and independent parameter for the overall survival of patients with a bladder carcinoma.
Immunohistochemical hTERT proof in control tissues. In normal cervix epithelium, Frost et al (33) showed immunohistochemical proof of hTERT in the basal and supra basal layers. Depending on the degree of dysplasia, hTERT was also expressed in the higher epithelial layers. With the same monoclonal antibodies (clone 4B1) Wada et al (43) demonstrated basal and somewhat stronger parabasal hTERT in normal vulva mucosa. In paraffin sections, Yan et al (21) used four anti-hTERT antibodies which we had also used (Table II) : the polyclonal antibody by Oncogene (PC563; Ab 1) which in our study was very weak; the polyclonal ab177 antibody (in our study Ab 7); the polyclonal Ab 2 by Calbiochem (code 582005, in our study Ab 4) and the monoclonal NCI-LhTERT antibody (in our study Ab 3). The authors demonstrated only very little hTERT expression in the basal layer of bladder tissue. Hiyama et al (17) , on the other hand, were able to give immunohistochemical evidence in paraffin sections of hTERT expression in a series of normal cells using the anti-EST2 antibody (in our study Ab 2): in basal keratinocytes of the skin, in basal cells of the endometrium and in epithelial cells from the mamma, in lymphocytes from tonsils, spleen, thymus, in lymphocytic infiltrates and trophoblasts from placenta. Volpi et al (69) reported nuclear, nucleolar and cytoplasmic proof of hTERT with a monoclonal antibody Tel 366-10 in different cell lines and in normal tissue (skin, prostate, mamma, cervix, bladder, kidney, pancreas and colon). Using the monoclonal NCL-hTERT, Luzar et al (49) found the lowest hTERT expression in normal larynx epithelium from control persons (mean hTERT index 0.17) in comparison to increasing expression in hyperplastic tissue (0.44), in basal hyperplasia (0.54), atypical hyperplasia (0.91), carcinoma in situ (1.05) and in larynx carcinoma (0.96).
In the present study we investigated tissue from patients without tumors. The tissues originated from patients of our clinic with squamous epithelial tissue which was normal only in part, being taken from inflamed tissue or tissue which was hyperplastic or to varying degrees dysplastic. Independent of the polyclonal and monoclonal antibodies used, the hTERT expression was localized in normal squamous tissues in the basal to parabasal layers, in dysplastic squamous epithelium over the entire epithelium. Immunoreactive hTERT scores also varied: Table VI and Fig. 3 . In control tissues hTERT scores were also the lowest with antibodies Ab 2 and Ab 6, as was the case in tissues from HNSCC ( Figs. 1 and 2) .
Telomerase activity was significantly higher in oral control tissues than in extraoral control tissues (p=0.023), as was the expression of control antibodies Ki-67 (p=0.006) and CD45 (p=0.032). hTERT expression was also higher in the oral control tissues with antibodies Ab 2 to Ab 8 than in the extraoral tissues, with Ab 7 significantly higher (p=0.010). In contrast to this, hTERT scores were higher with Ab 9 to Ab 11 in extraoral tissues than in oral tissues, reaching significance with Ab 11 (p=0.043). Comparison of the scores of all antibodies shows that the scores diverged significantly between the Ab 3 (NCL-hTERT) and the anti-nucleolin antibody (Ab 13): p=0.013 (U test). There was a correlation between the level of telomerase and the immunoreactive scores (¯2 test: p>0.05).
As was the case in tumor patient tissues containing no epithelial cells, control patient tissues containing no squamous epithelial cells (not listed in Results) only rarely showed nuclear marking of lymphocytic infiltration in the stroma with the antibodies Ab 4, Ab 6 or Ab 8 to Ab 11. Endothelia were marked predominantly with hTERT antibodies Ab 4, Ab 8, Ab 9 to Ab 11.
Nuclear demonstration of hTERT in frozen sections and nuclear demonstration of antibodies showing the best nuclear hTERT staining. Eleven antibodies, Ab 1 to Ab 11 (Table II) were tested in our study for nuclear demonstration of hTERT on frozen sections. Among them was also the controversial NCL-hTERT antibody (23) , Ab 3 of our study. We started work with the four antibodies available to us: Ab 1 to Ab 4. The immunoreactive scores (IRS) achieved in HNSCC with the polyclonal antibody Ab 1 (code PC563) by Oncogene/ Calbiochem were so low that it can be considered unsuitable for frozen sections. As was the case in Yan et al (21) , the nuclear staining obtained with our Ab 1 was ambiguous, and we abandoned this antibody.
With the other three antibodies, the two polyclonal antibodies code EST21-A (Ab 2) and code 582005 (Ab 4) and the monoclonal NCL-L-hTERT (clone 44F12, Ab 3), we worked out the best immunohistological localization of hTERT in the nuclei of the frozen sections. These antibodies had already been used successfully by Hiyama et al (17) , , Yan et al (21) and Park et al (22) in paraffinembedded material (tissue, cells). To achieve nuclear staining in frozen sections in our study, methanol-acetone fixation followed by pretreatment in a steamer in a slightly acidic buffer proved the most suitable method. Taylor et al (70, 71) had carried out comparisons using immunohistochemical methods as we had between diverse antibodies on paraffin sections without pretreating the sections and after pretreatment in the microwave, autoclave, and steamer. Only with some antibodies did Taylor et al find best results after pretreatment in the steamer. Steamers have been used only rarely for frozen sections (72) and up to now not for anti-hTERT antibodies. We observed occasionally diffuse or a cytoplasmic staining after pretreatment in the steamer. hTERT staining in frozen sections without pretreatment in the steamer was successful predominantly in cytoplasm and only in a few isolated cells with Ab 1 to Ab 4 and the other anti-hTERT antibodies (Table II) . For determining the semiquantitative immunoreactive hTERT scores we included only nuclear antibody marking. We agree with Poremba et al (20) , who regarded cytoplasmic staining as non-specific and rated it as unlabeled. We recorded cytoplasmic staining as negative, i.e., showing no nuclear marking.
The polyclonal anti-hTERT antibody code EST21-A (Ab 2, Table II ) is directed against 16 amino acids of the middle region of the hTERT sequence. It produced the weakest nuclear staining on frozen sections in our preliminary examinations. This was confirmed on an adequate number of tissues (Figs. 1-3 and Tables III-VI) . Hiyama et al (17, (73) (74) (75) (76) achieved strong nuclear hTERT staining with this same antibody on paraffinembedded cells and biopsies, suggesting that EST21-A is less effective for frozen sections. Miyazu et al (75) also demonstrated pronounced hTERT expression on paraffin sections from lung tumors and normal lung squamous tissue. The EST21-A antibody actually produced significant demonstration of hTERT in 23 patients with histopathologically normal epithelium, and patients with higher hTERT expression in epithelial tissue developed lung carcimomas. Similar results were recorded by Hashimoto et al (76) in paraffin sections of pancreas tumors and normal pancreas tissue. Higher hTERT expression in pancreatic epithelial tissue points to a malignant transformation.
We achieved particularly good nuclear and even nucleolar marking with the monoclonal antibody NCL-L-hTERT (Ab 3), which is directed against the amino acid sequence 173-320 of the N-terminal domain of the hTERT sequence. This antibody has been applied by many authors in recent years to demonstrate hTERT. Wu et al (23) summarize the most important work done up to 2006 but comment on the use of the NCL-LhTERT for immunohistochemical demonstration of hTERT. From their spectrometric investigation of the antibody, supplemented with findings from two-dimensional gel analysis and immunofluorescence, they concluded that the antibody NCL-hTERT targets nucleolin rather than hTERT.
Having acquainted ourselves with the work by Wu et al (23), we were particularly careful in evaluating the score values obtained with the controversial antibody. To reinforce our findings we supplemented our study with an additional anti-nucleolin antibody (Ab 13, Table II ). As already shown by Ohkoudo et al (77) the immunohistochemical picture after we applied the anti-nucleolin antibody occasionally resembled those with the anti-hTERT antibody NCL-L-hTERT (Ab 3: Fig. 5a ).
In their study, Wu et al (23) also included a polyclonal antibody by Calbiochem (code 581400) directed against the amino acid sequences 568-581, the central domain of the hTERT peptide sequence. We suspect that this antibody is comparable to the two polyclonal antibodies by Calbiochem, Ab 4 (code 582005) and Ab 6 (code 582000) used in our study. Ab 4 and Ab 6 are directed against an unknown immunogen in the internal region of the hTERT sequence. In our preliminary investigations the antibody code 582005 (Ab 4, Fig. 5b ) displayed clear staining of the entire nucleus with simultaneous cytoplasmic staining and non-specific background staining. Our results with the frozen sections were comparable to those published for paraffin sections (18) (19) (20) (21) (22) 64, 78, 79) . Like Yan et al (21) , we found that this pronounced cytoplasmic staining made evaluation of immunoreactive scores difficult. By contrast, the distinct nucleolar picture presented by the antibody NCL-LhTERT (Ab 3, Fig. 5a ) made semiquantitative detection of score values easier.
The values rendered with the polyclonal TERT (H-231) antibody, code sc-7212 (Ab 5) ranged from very low to negative. This antibody is recommended by the manufacturer for immunofluorescence and has been reported by Wei and Younes (62) , Hoang-Vu et al (54) and Boltze et al (80) to give good proof of hTERT in a variety of different tumors. However, given the results we obtained, we abandoned its further use and did not report in detail the results obtained with it.
With the polyclonal antibody code 582000 (Ab 6, Table V) background staining was markedly weaker than with antibody code 582005 (Ab 4). Just as with hTERT scores with Ab 2 (code EST21-A), however, values with Ab 6 were much lower than those with other antibodies, particularly with the antibody Calbiochem code 582005 (Ab 4) (Figs. 1-3) .
We investigated two polyclonal anti-hTERT antibodies by Abcam (our Ab 7 = code ab177 and its successor, code ab23699, our Ab 8, Table II ). Both showed nuclear staining (Ab 7: Fig. 5c and Ab 8: Fig. 5d ). hTERT score values were higher with the antibody code ab177 (Figs. 1-3 ). With the same antibody, Yan et al (21) had obtained only cytoplasmic staining in paraffin slides of telomerase-positive and telomerasenegative tissues.
To validate the results of their immunohistochemical study on giant cell tumors, Forsyth et al (81) applied the monoclonal antibody NCL-hTERT as well as the same polyclonal antihTERT antibody code 600-401-252 (Rockland) used by Wu et al (23) (in our study Ab 9, Table II ). The two antibodies yielded similar nuclear staining of osteoclasts and mononuclear cells, with one or more than one small-to-large aggregates in the nucleus. Applying the same antibody, we observed nuclear staining of carcinomas, squamous epithelial cells, endothelial cells and occasional blood cells. Forsyth et al (81) also observed, along with a staining of nuclear aggregates, a diffuse distribution of nuclear staining and fine granular cytoplasmic staining. Neither Forsyth et al (81) nor we observed any cytoplasmic staining with the antibody NCL-hTERT (our Ab 3). Wu et al (23, and supplementary Fig. 1 therein) consider the polyclonal antibody by Rockland, which is directed against the C-terminal domain of the hTERT sequence (aa 1104-1123), to be the most important of the anti-hTERT antibodies studied by them. Our immunohistological images with the code 600-401-252 antibody by Rockland (Figs. 1-3 and 5e) displayed clear nuclear marking and cytoplasmic staining. It is noteworthy that the hTERT scores were higher in the squamous epithelial cells of extraoral control tissue than in the oral tissues (Fig. 3) .
We obtained clear nuclear marking with both of the monoclonal anti-hTERT antibodies by Novus Biologicals (Table II) Ab 10 and Ab 11 (clone 2D8, code NB 100-297 and clone 2C4, code NB 100-317). In most cases the entire nucleus was marked (see Ab 10: Fig. 5f ). In our investigation with Ab 11 (code NB 100-317) the cytoplasm was also partially marked. Both are IgM antibodies, as opposed to all other anti-hTERT antibodies used by us, which belong to the IgG classification. The two antibodies are directed against the entire length of the hTERT peptide sequence (aa 1-1132). The code NB100-317 antibody was also studied by Wu et al (23) . Using immunofluorescence, Masutomi et al (82) detected a subcellular localization of hTERT on mortal and immortal human cell lines with the monoclonal anti-hTERT antibody clone 2C4 (Ab 11, Table II ). The nuclear pattern with this antibody was comparable to a polyclonal (not specified) anti-hTERT antibody. In addition, the authors found nucleoplasmatic staining with this antibody, corroborating our results. Lin et al (83) , using the monoclonal anti-hTERT antibody clone 2C4 by Abcam in mutational exclusion studies, were able to confirm a diffuse nuclear localization with the antibody.
Using the three control antibodies Ab 12 to Ab 14 (Table II) we also applied the steamer for the immunohistochemical demonstration of Ki-67, nucleolin and CD45 expression. However, pretreatment of the frozen sections was not crucial for these antibodies. Originally we used the monoclonal antibody PCNA (proliferating cell nuclear antigen, clone PC 10, code M0879, Dako) as a marker for proliferation instead of Ki-67, but it labeled only cells in the S-phase, in which telomerase and hTERT expression are at their maximum (84) . The PCNA score values yielded by our immunohistochemical processing were however very low, so we used Ki-67 (Ab 12) throughout the entire study in spite of the fact that with this antibody all cells in the cell cycle are marked. Ki-67 (score values in Tables III-VI) had the further advantage that it allowed easy recognition of any small carcinomatous areas on the frozen sections.
Specificity of anti-hTERT antibodies applied. In our study the antibody Ab 3 (NCL-L-hTERT, Table II ) characteristically showed predominantly nucleolar staining (Fig. 5a) . We extended the scope of our study with immunoabsorption tests to determine whether Ab 3 and other anti-hTERT antibodies indicate nucleolin. Most antibodies in our study were absorbed with one nucleolin peptide and two hTERT peptides. Thus, we included an anti-nucleolin antibody (Ab 13, Table II) . As a peptide control we used albumin, as had Frost et al (33) . Neither in the experiments of Frost et al nor in ours did the albumin inhibit any of the antibodies. Frost et al (33) used their own monoclonal antibody [clone 4B1 (46) ] against hTERT sequence aa 549-831 for the immunoabsorption and were able to completely block the diluted antibody with 375 ng hTERT protein. In the immunoabsorption of a polyclonal anti-prostaglandin receptor antibody to determine antibody specificity, Nakamura et al (85) used 16 times more peptide than antibody and achieved the same effect as had Frost et al (33) . Blocking tests have also been used to determine antibody specificity. Klinck et al (86) investigated 4 monoclonal antibodies on pancreas sections using immunofluorescent techniques before and after peptide blocking and were thus able to characterize the antibodies.
To demonstrate successful absorption, we, like Frost et al (33) , subjected the antibodies to immunohistochemical investigation with and without absorption. We increased the number of sections included to minimize subjectivity in score evaluation. This in turn required substantial volumes of antibody, and the amounts of peptide we used achieved in fact only partial antibody absorption (Fig. 4) . The fact that antibody Ab 8 was only partially blocked by their homologous peptides ab23699 indicates that the amounts of peptide used were insufficient. It is also conceivable that peptides and antibodies were only partially homologous.
Absorption of the antibodies by the peptide EST-21-P (homologous to Ab 2 in our study) was low: Ab 10 (50%), Ab 9 (33%), Ab 3 (30%), Ab 7 (28%), Ab 4 (26%) and Ab 8 (no absorption) (Fig. 4 ). Ab 11 (NB 100-317) absorption with EST21-P was not tested.
The polyclonal antibody ab23699 (Ab 8) was 59% absorbed (score after absorption 41%) by the homologous peptide ab24029. The percentages for other antibodies absorbed by this peptide were lower: Ab 11 (56%), Ab 3 (46%), Ab 7 (35%), Ab 10 (27%), Ab 9 (24%) and Ab 4 (21%). Only 8% of the anti-nucleolin antibody (Ab 13, Table II ) was absorbed by the hTERT peptide ab24029 (score after absorption 92%).
The homologous nucleolin peptide ab25315 absorbed 100% of the anti-nucleolin antibody (Ab 13, Table II ) but did not in any test block the antibodies Ab 4, Ab 9, Ab 10 or Ab 11. The other antibodies were absorbed by the nucleolin peptide as follows: Ab 8 (60%), Ab 3 (21%), Ab 7 (17%). Only 21% of the anti-hTERT antibody NCL-L-hTERT, which according to Wu et al (23) is an anti-nucleolin antibody, was absorbed by the nucleolin peptide, but 30% and 46% of the same antibody was also absorbed respectively by the two hTERT peptides EST21-P and ab24029. Although our immunoabsorption results are not unambiguous, they nevertheless support the view that not only nucleolin is demonstrated by the antibody NCL-L-hTERT. We may conclude that the antibody Ab 3 is not exclusively directed against nucleolin, but that the antibodies Ab 4, Ab 9, Ab 10 and Ab 11 are not directed against nucleolin (Fig. 4) . While the polyclonal antibody Ab 4 is directed against the (unspecified) internal hTERT region and the polyclonal Ab 9 against the C terminal domain (aa 1104-1123), the monoclonal antibodies Ab 10 and Ab 11 are directed against the entire length of the hTERT peptide sequence.
Proof of hTERT and telomerase function. With anti-hTERT antibodies 2-4 and 6-11 we were able to demonstrate nuclear hTERT expression of varying intensity (Figs. 1-3 and 5) , albeit directed at different hTERT domains. Whether this test is related to a function of telomerase can not be determined on the basis of the immunohistochemical scores. From the studies by Etheridge et al (59) and Wong et al (87) it is known that temporary hTERT expression is concentrated in the nucleoplasm of human cells, particularly in the nucleolus. Zhu et al (88) confirmed this location to Cajal bodies with fluorescent in situ hybridization in HeLa cells and in some other carcinoma cell lines. Yang et al (89) found through fluorescence tagging experiments that the nucleolar localization of hTERT depends on the N-terminus (aa 1-15) of hTERT (23) and is associated with telomerase function. This localization is cell cycle dependent. Lin et al (83) were able to show by hTERT mutation of residues 254 and 265 in HeLa cells that the nucleolar binding of hTERT and telomerase function are not identical and that mutational inactivation of hTERT C-terminals 965-981 maintains telomerase function despite suspension of nucleolar binding in human and mouse cell lines (90) .
The third antibody used in this study (NCL hTERT, Table II) , with its typical nucleolar marking (Fig. 5a) , is directed against an N terminal hTERT sequence. Lam et al (63) verified with the NCL-L-hTERT antibody that telomerase and nucleolin interact with one another and display the same intracellular distribution. They concluded that despite the criticism of Wu et al (23) telomerase activity can also be demonstrated with this antibody. Nucleolin is a nucleolar phosphoprotein (91) used with nucleolin-specific antibodies to identify nucleoli (92). Khurts et al (91) revealed that nucleolin interacts with telomerase and changes its subcellular localization. In this process it can bind with hTERT, with significant consequences for its nucleolar localization. (10, 93) demonstrated telomerase in carcinoma-free tumor margins in head and neck tumors and addressed the question of whether the presence of telomerase activation occurs by lymphocytic infiltration in the tissue or whether it was an expression of field cancerization (1, 2) in the region surrounding the tumor. In previous examinations we had demonstrated a limited correlation between telomerase activity and lymphocyte infiltration in tumor margin tissues (13, 14, 94, 95) .
Cells which may be responsible for telomerase activity outside the carcinoma (tumor margin tissue, tumor distant tissue, and control tissue). Mao et al
Hiyama et al (94) , Counter et al (96) and Broccoli et al (97) demonstrated a low level of telomerase activity in hematogenic cells which was higher in stimulated lymphocytes (94, 97, 98) . Shay and Wright (99) observed telomerase activity of the mononuclear cells in 124 blood samples the intensity of which varied with the number of cells used.
Detectable lymphocytic infiltration has been described in HNSCC tumor margin tissue (100-103). We applied a monoclonal CD45 antibody (Ab 14, Table II ) to evaluate lymphocytic-monocytic infiltrates. Statistical comparison revealed a significant variance between the CD45 scores and the extremely low hTERT score values with antibodies Ab 2 and Ab 6 in the tumor margin of squamous cell carcinoma and with antibody Ab 2 in tumor distant tissue of SCC patients. In the tumor margin tissue there was no significant difference between hTERT scores revealed by clearly marked antibodies (Ab 3, Ab 4 and Ab 7) and the CD45 scores. The CD45 scores were significantly higher in oral control tissues than in extraoral control tissues (p=0.032) (Table VI) . In earlier studies we rarely observed a correlation between telomerase levels in the tumor margin and tumor distant tissues of HNSCC and the lymphocytic infiltrates detected by histopathology (13, 14) . We demonstrated only isolated hTERT marked cells in the stroma of these tissues.
To check for field cancerization (1,2) in tumor margin tissue which had been histopathologically characterized as carcinoma-free, we investigated the hTERT scores of squamous epithelial cells in the tissues (Fig. 2 and Table V) (93) of carcinoma-free tumor margin tissues some of which were dysplastic. In the present study we found positive telomerase values (13) (14) (15) in 52% of the tumor margin and 30% of the tumor distant tissues of patients with squamous cell carcinomas.
Up to now only few tumor margin tissues from head and neck tumors have been inspected for hTERT. Luzar et al (49) compared immunohistochemical proof of hTERT detected with the NCL-hTERT antibody (our Ab 3) with RT-PCR results in tumor margin tissues from larynx carcinomas showing varying degrees of hyperplasia. Both methods showed that increasing hTERT expression is an early event in larynx carcinogenesis. This concurs with the results of Eissa et al (105) , who with real-time PCR and fluorescence cytophotometry found lower hTERT levels in larynx tumor margin tissue than in the carcinomas.
The present investigations showed that in addition to the lymphocytic infiltrates in carcinoma-free tumor margin tissues, hTERT was also expressed in squamous epithelial cells distributed in the basal but also in the suprabasal layer and throughout the entire squamous epithelium of the same tissues. hTERT expression was highest when the antibodies Ab 3, Ab 4 and Ab 7 (Table II) were applied (Fig. 2, Table IV) . ¯2 test registered a correlation between hTERT scores and telomerase activation. The result emerging from these investigations was that lymphocytic infiltration and especially field cancerization of the squamous epithelium in carcinoma-free resection margins are the cause of telomerase activity in these tissues. Whether hTERT is a suitable target for adjuvant therapy of head and neck tumors, as is suggested by Freier et al (51) , cannot be determined in our experiments unambiguously.
For our study of hTERT-detection in the squamous epithelia of carcinoma free tumor margins and tumor distant tissues (Fig. 2) we applied antibodies Ab 2, Ab 3, Ab 4, Ab 6 and Ab 7. Ab 3 (code NCL-hTERT), Ab 4 (code 582005) and Ab 7 (code ab177) were particularly suited for causing sensitive hTERT reaction in field cancerization of these tissues or for demonstrating disseminated individual carcinoma cells (minimal residual disease/MRD). Ab 8 to Ab 11 were not applied to tumor margin and tumor distant tissues, but in immunohistochemical testing exhibited intense nuclear and/ or nucleolar marking in carcinoma (Table III, Fig. 1 ) and in the squamous epithelium of the HNSCC tumor center (Table IV , Fig. 1 ). That is why Ab 8 (code ab23699), Ab 9 (code 600-401-252), Ab 10 (code NB 100-297) and Ab 11 (code NB 100-317) are also well suited for the detection of hTERT expression and field cancerization. Considering the evidence given by Wu et al (23, 106) and our results for immunoabsorption, the following conclusion can be drawn: antibodies Ab 4 and Ab 9 to Ab 11 are particularly well suited for identifying field cancerization and for proof of MRD. We were unable to demonstrate absorption of these antibodies with the nucleolin peptide ab25315 (Fig. 4) . If necessary Ab 3 is also useful for demonstrating both field cancerization and MRD. In the Fisher exact test a correlation appears between the level of hTERT scores for these 5 antibodies and telomerase activity (Table III) : p-values between 0.086 (Ab 11) and 0.752 (Ab 3).
We agree with Lantuejoul et al (107) , however, that it is important to develop new anti-hTERT antibodies against proteins or peptides which do not react or cross-react with nucleolin. Manufacturers of the NCL-L-hTERT antibody should feel prompted by the critical publications of Wu et al to re-examine the antigen specificity of their antibody. Xiao et al (106) conclude from their studies on culture cells and tissues fixated in formalin that chicken IgG antibodies can have definite advantages over the commonly used mammal IgG antibodies and exhibit less non-specific staining. Irrespective of the afore-mentioned objections, many authors continue to use the monoclonal NCL-L-hTERT for immunohistochemical proof of hTERT (63, 66, (107) (108) (109) (110) (111) (112) .
